Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Machiels

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
ESMO Open|November 29, 2021
Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neckB Keam, J-P Machiels, H R Kim, et al.
Frontiers in Oncology|October 22, 2025
Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinomaJ-P Machiels, Y Tao, L Licitra, et al.
BMC Cancer|May 21, 2021
Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort studyC van Marcke, N Honoré, A van der Elst, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2022
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III studyA Psyrri, J Fayette, K Harrington, et al.
ESMO Open|August 20, 2022
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter studyM Simonelli, E Garralda, F Eskens, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
ESMO Open|November 29, 2021
Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neckB Keam, J-P Machiels, H R Kim, et al.
Frontiers in Oncology|October 22, 2025
Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinomaJ-P Machiels, Y Tao, L Licitra, et al.
BMC Cancer|May 21, 2021
Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort studyC van Marcke, N Honoré, A van der Elst, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2022
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III studyA Psyrri, J Fayette, K Harrington, et al.
ESMO Open|August 20, 2022
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter studyM Simonelli, E Garralda, F Eskens, et al.
Pageof 7